FOLFIRINOX May Offer Benefit in Locally Advanced Pancreatic Cancer
Pancreatic cancer accounts for 4.5% of all cancer-related deaths and is one of the deadliest cancers with 5-year survival rates of <5%. The chemotherapeutic regimen, FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is widely used in the management of metastatic pancreatic cancer, but its benefit in locally advanced pancreatic cancer is less well defined. Read more.

Biosimilar IV and SC Trastuzumab in Clinical Practice
For patients with human epidermal growth factor receptor 2-positive breast cancer, FDA approval of trastuzumab in 1998 was a game changer. Between 1998 and 2019, the only formulation of trastuzumab that was available in the United States was the IV form of the biological agent. The release of an SC formulation as well as that of several biosimilars followed the expiration of trastuzumab’s patent in 2019. Read more.

How Useful Is the URAC Pharmacy-Reported HCV Completion of Therapy Measure?
In 2019, the nonprofit Utilization Review Accreditation Commission (URAC) implemented a pharmacy measure that defines the treatment of chronic hepatitis C virus (HCV) completion of therapy. It measures the percentage of patients aged 18 years and older who initiated antiviral therapy during the measurement year for treatment of chronic HCV and who completed the minimum intended duration of therapy without significant gaps. Read more.